|
|
News Breaks | | | | October 10, 2012 | | 09:16 EDT |  | CBLI | Cleveland BioLabs and Incuron announce start of Phase 1 trial for CBL0137
Cleveland BioLabs and Incuron, LLC, a joint venture between the company and Bioprocess Capital Ventures, announced that the first patient was dosed in a Phase 1, single agent, dose escalation study of the oral formulation of CBL0137 in subjects with advanced solid tumors that are resistant or refractory to standard of care treatment. The trial is being conducted at five leading oncology centers in the Russian Federation. A pre-Investigational New Drug Application, or IND, meeting was conducted over the summer with the U.S. Food and Drug Administration in anticipation of filing an IND in Q1 of 2013. | |
|
News For CBLI From The Last 14 Days Check below for free stories on CBLI the last two weeks. |
|
|
| May 9, 2013 | | 07:50 EDT |  | CBLI | Cleveland BioLabs reports Q1 EPS (22c), one estimate (17c)
Reports Q1 revenue $1.37M, one estimate $1.73M. | |
|
|
|
|
|
|
